Our Pricing

Understanding Mounjaro 5mg for Weight Loss

Published on: June 03, 2026

Mounjaro 5mg is the second maintenance dose in the tirzepatide treatment pathway, prescribed after patients successfully tolerate the initial 2.5mg starter dose. This GLP-1 and GIP dual receptor agonist has demonstrated significant weight loss outcomes in clinical trials, with patients progressing through a carefully titrated dosing schedule under medical supervision. At Cured Pharmacy, we provide Mounjaro 5mg from £124.99 following a free online clinical assessment by our UK-registered prescribers.

What Is Mounjaro 5mg and How Does It Work?

Mounjaro 5mg contains tirzepatide, a once-weekly injectable medication that activates both GLP-1 and GIP receptors to regulate appetite and blood sugar levels [1]. This dual-action mechanism distinguishes it from single-receptor agonists, contributing to its efficacy in clinical weight management programmes. The 5mg dose represents the second step in a structured titration schedule designed to minimise gastrointestinal side effects whilst optimising therapeutic benefit.

Patients typically spend four weeks on the 2.5mg starter dose before advancing to Mounjaro 5mg, allowing the body to adapt gradually to the medication's effects [2]. This escalation strategy, validated in the SURMOUNT clinical trial programme, helps maintain tolerability whilst achieving progressive weight reduction. The medication works by slowing gastric emptying, enhancing satiety signals, and improving insulin sensitivity in response to meals.

The Science Behind Tirzepatide's Dual Mechanism

Unlike semaglutide-based treatments that target only GLP-1 receptors, tirzepatide in Mounjaro 5mg engages both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors [3]. This dual agonism creates synergistic effects on weight loss, with GIP receptors potentially reducing the compensatory increase in appetite that sometimes limits single-agonist treatments. Clinical pharmacology studies demonstrate that this combination enhances metabolic improvements beyond what either pathway achieves alone.

Mounjaro 5mg Dosage and Administration Guidelines

The standard Mounjaro 5mg dosing protocol involves one subcutaneous injection weekly, administered on the same day each week at any time regardless of meals [4]. Patients inject into the abdomen, thigh, or upper arm using the pre-filled KwikPen device, rotating injection sites to prevent lipohypertrophy. If a dose is missed, it should be administered within four days; beyond that window, skip the missed dose and resume the regular schedule.

Most patients remain on Mounjaro 5mg for at least four weeks before considering escalation to 7.5mg, though some may stay at this dose if achieving satisfactory weight loss with minimal side effects. Dose progression decisions require clinical review by a prescriber, who evaluates weight loss trajectory, tolerability, and individual patient factors. The maximum licensed dose is 15mg weekly, reached through gradual increments every four weeks as clinically appropriate.

Expected Weight Loss Results with Mounjaro 5mg

In the SURMOUNT-1 trial, participants using tirzepatide (including those at the 5mg maintenance dose during titration) achieved an average weight reduction of 15-20% of baseline body weight over 72 weeks [5]. Individual results vary considerably based on adherence, lifestyle modifications, starting BMI, and metabolic factors. Patients typically notice appetite suppression within the first week of starting Mounjaro 5mg, with measurable weight loss becoming evident after 4-8 weeks of consistent treatment.

The 5mg dose often produces more pronounced effects than the 2.5mg starter dose, as therapeutic drug levels accumulate and patients adapt their eating patterns to the enhanced satiety signals. Clinical experience shows that combining Mounjaro 5mg with structured dietary changes and regular physical activity optimises outcomes, though the medication provides significant benefit even without intensive lifestyle intervention. Prescribers monitor progress monthly to assess whether dose escalation or maintenance best serves individual treatment goals.

Comparing Mounjaro 5mg to Other Weight Loss Treatments

Head-to-head trials demonstrate that tirzepatide at therapeutic doses produces greater average weight loss than semaglutide 1mg (Wegovy's maximum dose), with approximately 5-7% additional body weight reduction in comparative studies [6]. The 5mg dose of Mounjaro sits mid-range in the titration schedule, offering substantial efficacy whilst remaining below the maximum 15mg dose. Patients who plateau at lower doses may benefit from escalation, whilst those experiencing side effects might maintain the 5mg dose longer before advancing.

Common Side Effects of Mounjaro 5mg and Management Strategies

The most frequently reported side effects with Mounjaro 5mg include nausea, diarrhoea, decreased appetite, vomiting, and constipation [7]. These gastrointestinal symptoms typically emerge or intensify when escalating from 2.5mg to 5mg, though the gradual titration schedule minimises their severity compared to starting at higher doses. Most patients find these effects diminish within 2-3 weeks as the body adapts, though some experience persistent mild symptoms throughout treatment.

Managing side effects involves practical strategies: eating smaller, more frequent meals; avoiding high-fat foods that delay gastric emptying further; staying well-hydrated; and timing the injection for evenings if nausea proves problematic. Severe or persistent vomiting, signs of pancreatitis (severe abdominal pain radiating to the back), or symptoms of thyroid tumours warrant immediate medical attention and treatment discontinuation. Our clinical team at Cured Pharmacy provides ongoing support to help patients navigate these adjustments whilst maintaining treatment adherence.

Who Can Use Mounjaro 5mg for Weight Loss?

Mounjaro 5mg is licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [8]. Prescribers assess suitability through comprehensive medical history review, evaluating contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease. Pregnancy, breastfeeding, and plans to conceive within the treatment period represent absolute contraindications.

The 5mg dose specifically suits patients who have successfully completed the 2.5mg starter phase without significant adverse effects and require continued dose escalation toward their target weight. Not all patients progress beyond Mounjaro 5mg—some achieve satisfactory results at this dose and maintain it long-term, whilst others continue titrating upward every four weeks. Clinical assessment determines the optimal individualised pathway, balancing efficacy against tolerability and patient-specific factors.

Mounjaro 5mg and Pre-existing Medical Conditions

Patients with type 2 diabetes require careful monitoring when using Mounjaro 5mg, particularly if taking concurrent insulin or sulfonylureas, as the combination increases hypoglycaemia risk. Those with diabetic retinopathy should be aware of potential rapid glycaemic improvement effects on eye health, necessitating ophthalmological surveillance. Renal impairment doesn't require dose adjustment, though dehydration from gastrointestinal side effects could worsen kidney function in vulnerable patients, making hydration maintenance critical.

Purchasing Mounjaro 5mg from Cured Pharmacy

At Cured Pharmacy, Mounjaro 5mg is available from £124.99 following a free online clinical assessment completed in under three minutes. Our UK-registered prescribers review your medical history, current medications, and weight loss goals to determine suitability, with most assessments approved within hours during business days. We supply only genuine UK-licensed Mounjaro manufactured by Eli Lilly, delivered in discreet packaging with next-day delivery options available.

New patients can Save £20 on their first order using code Weightlossnew, reducing the initial cost to £124.99. Our transparent pricing model shows all costs upfront before consultation, with no hidden fees or subscription requirements. Superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all dispensing, ensuring every prescription meets GPhC standards and MHRA regulations. Ongoing treatment requires monthly clinical reviews to monitor progress, adjust dosing as needed, and ensure continued safety throughout your weight loss journey.

Scientific References

1. Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 13 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 13 August 2026]
3. Coskun, T., Sloop, K. W., Loghin, C., et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3-14. [accessed 13 August 2026]
4. Electronic Medicines Compendium. (2023). Mounjaro 5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. Eli Lilly and Company Limited. [accessed 13 August 2026]
5. Garvey, W. T., Batterham, R. L., Bhatta, M., et al. (2023). Two-year effects of tirzepatide on glycaemic control and body weight in participants with type 2 diabetes mellitus and obesity: 104-week results from SURMOUNT-1. Diabetes, Obesity and Metabolism, 25(11), 3184-3199. [accessed 13 August 2026]
6. Rosenstock, J., Wysham, C., Frías, J. P., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet, 398(10295), 143-155. [accessed 13 August 2026]
7. Dahl, D., Onishi, Y., Norwood, P., et al. (2022). Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: The SURPASS-5 randomized clinical trial. JAMA, 327(6), 534-545. [accessed 13 August 2026]
8. National Institute for Health and Care Excellence. (2023). Tirzepatide for treating obesity [ID6218]: Final scope. NICE. [accessed 13 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.